NewLimit
Claimed
Agent33Agent Readiness: 33/100. Below median. Measured by StartupHub.ai. Median 41.Trust63Data Trust: 63/100. Above median. Measured by StartupHub.ai. Median 61.NewLimit is developing epigenetic therapies to extend human healthspan by reprogramming aging cells.
About
NewLimit is a biotechnology company focused on extending human healthspan by developing epigenetic reprogramming medicines. They leverage advanced genomics, machine learning, and cellular biology to identify and manipulate epigenetic drivers of aging, aiming to restore youthful function in aged cells and treat age-related diseases. Their approach involves a "lab in a loop" system where AI models predict and experiments validate therapeutic candidates.
Listed competitors
Also in this space
A global oncology company developing and commercializing innovative cancer treatments.
Shares Biotech, HealthTech
AI-powered biotechnology company developing RNA therapeutics for genetic diseases.
Shares Biotech, Drug Discovery
AI-driven drug discovery company developing novel medicines for unmet patient needs.
Shares Biotech, HealthTech
Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.
Shares Biotech, HealthTech
Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.
Shares Biotech, HealthTech
A precision biotechnology company developing a blood-based platform for early cancer detection and treatment.
Shares Biotech, HealthTech
Key facts
- Website
- newlimit.com
- Headquarters
- San Francisco Bay Area, USA
- Founded
- 2022
- Total funding
- $215M (Series B Extension)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 20 Oct 2025 | Series B Extension | $45M | $1.6B | |
| 6 May 2025 | Series B | $130M | $810M | Kleiner Perkins |
| 8 May 2023 | Series A | $40M | Founders Fund |
Tech stack
Detected on newlimit.com, last scanned 21 Oct 2026. Run your own scan
- Frontend
- Tailwind CSS
- CMS / Builders
- Webflow
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Email marketing
- Substack
NewLimit scores 44. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is NewLimit trustworthy and reputable?
StartupHub's Data Trust & Reputation score for NewLimit is 63 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has NewLimit raised?
NewLimit has raised a total of $215M in funding. The most recent round on record is Series B Extension.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for NewLimit
